Clinical trials
Metastatic clinical trials
Below are recruiting metastatic clinical trials, each written for real people, not researchers. We’re tracking 2,342 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05907681Recruiting
Study outcomes after precise targeted radiation for metastatic breast cancer
This study follows people with breast cancer that has spread to other parts of the body who receive a highly precise form of radiation (like IMRT, SBRT, or proton therapy). It aims to see how well this treatment strategy works and what outcomes patients experience.
SeoulAges 19–100 - NCT06887218RecruitingPhase 2
Testing a new combination for advanced colorectal cancer
This trial tests a combination of two drugs, regorafenib and 5-FU with leucovorin, for people with colorectal cancer that has spread and has not responded to at least two previous treatments. The goal is to see if this new mix can help shrink or control the cancer.
Houston, TexasAges 18 years+ - NCT06880198Recruiting
Study of Impact app for advanced melanoma patients on immunotherapy
This trial is testing whether a digital tool called Impact can help support patients with advanced melanoma who are receiving immunotherapy drugs like Nivolumab, alone or in combination. The goal is to see if the app helps manage treatment and improve outcomes.
NaplesAges 18 years+ - NCT06415487RecruitingPhase 1
Testing a new cell therapy for advanced EGFR-positive solid tumors
This trial tests a new cell therapy called ACE2016 for people with advanced solid tumors that have EGFR on their surface. It may be an option if you have tried at least two other treatments (including a targeted therapy) and your cancer is still growing.
San Diego, CaliforniaAges 18 years+ - NCT06877949Recruiting
PET/CT vs. CT Scan for Monitoring Metastatic Breast Cancer
This trial compares two types of scans (PET/CT and CT) to see which is better at monitoring metastatic breast cancer. If you are starting your first treatment for breast cancer that has spread to other parts of the body, this study may help determine the best way to track your disease.
AalborgAges 18 years+ - NCT06873763RecruitingPhase 1/Phase 2
Nelmastobart with chemo for advanced colorectal cancer
This trial tests a new immunotherapy drug, nelmastobart, combined with two standard chemotherapy drugs (trifluridine/tipiracil and bevacizumab) for people with advanced colorectal cancer that hasn't responded to other treatments. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Seongnam-si, Gyeonggi-doAges 19 years+ - NCT06875128RecruitingPhase 2
Liver-directed chemo with standard chemo for breast cancer
This trial tests if giving a high dose of chemotherapy directly into the liver, followed by standard chemotherapy, is safe and works better than standard chemo alone for people with breast cancer that has spread mostly to the liver.
Tampa, FloridaAges 18 years+ - NCT06861088RecruitingPhase 3
Kinisoquin for preventing blood clots in pancreatic cancer
This trial tests whether an investigational drug called Kinisoquin™ can help prevent blood clots in people with advanced pancreatic cancer who are starting their first chemotherapy. It may be a good option if you are looking for extra protection against clots during treatment.
Ventura, CaliforniaAges 18 years+ - NCT06864572Enrolling by invitationEarly Phase 1
New imaging tracer for metastatic prostate cancer
This trial tests a new radioactive tracer that may help doctors see and treat prostate cancer that has spread. The tracer attaches to cancer cells so they show up on scans, and may also help guide treatment.
BeijingAges 18–85 - NCT06866938RecruitingPhase 2
Second course of PSMA-targeted radiation for prostate cancer
This study tests giving the targeted radiation drug [177Lu]Lu-PSMA again to men whose prostate cancer has started growing after an earlier course of the same treatment. It aims to see if a second round can control the cancer again.
BordeauxAges 18 years+ - NCT05582772Recruiting
Supportive care for older men with metastatic prostate cancer
This study tests a phone-based supportive care program for older men with prostate cancer. It aims to help with day-to-day management while you’re receiving hormone-related cancer treatment.
Toronto, OntarioAges 65 years+ - NCT06849362Enrolling by invitation
Optimizing immunotherapy for advanced colorectal cancer
This study looks at how well different combinations of immunotherapy drugs work for advanced colorectal cancer that is MSS or MSI-L or pMMR. It reviews past patient records to see which treatments help control the disease and slow its growth.
Changsha, HunanAges Any age - NCT06852820RecruitingPhase 2
PSMA-targeted radioactive therapy for advanced liver cancer
This trial tests a radioactive treatment called 177Lu-PSMA-617 for advanced liver cancer that has not responded to first-line immunotherapy. You need a PSMA-PET scan first to see if your cancer absorbs the treatment.
Cleveland, OhioAges 18 years+ - NCT06854250RecruitingPhase 2
Cryoablation and low-dose chemo for metastatic prostate cancer
This trial tests freezing prostate tumors (cryoablation) combined with a low-dose chemotherapy pill (metronomic cyclophosphamide) for men with metastatic prostate cancer. The goal is to see if this combination can slow the cancer's growth and improve outcomes.
Guangzhou, GuangdongAges 18–80 - NCT06856837RecruitingPhase 2
Fruquintinib and Tislelizumab for advanced colorectal cancer
This trial tests a combination of two drugs, fruquintinib and tislelizumab, for people with a specific type of advanced colorectal cancer that has not spread to the liver. It is for those whose cancer is stable in certain DNA repair systems (MSS/pMMR) and who have already tried other treatments.
LinzAges 18 years+ - NCT06842498RecruitingPhase 2
FG-3246 for advanced prostate cancer
This trial tests a new drug called FG-3246, which targets a protein (CD46) on prostate cancer cells. It's for men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy, and who have had limited prior treatments.
Goodyear, ArizonaAges 18 years+ - NCT06833853Recruiting
Blood test study for women with advanced breast cancer
This study looks at a blood test that measures certain markers on cancer cells (CTCs) and genetic material in the blood (cfDNA/RNA) in women with metastatic breast cancer. It aims to better understand the cancer and guide treatment decisions.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06828263Recruiting
Imaging markers during PSMA therapy for prostate cancer
This trial is testing a new imaging approach during treatment with a radioactive drug (Lu-PSMA) for men with advanced prostate cancer that no longer responds to hormone therapy. The goal is to see if imaging changes can help predict how well the treatment is working.
GrenobleAges 18 years+ - NCT06833866RecruitingPhase 1
Testing a natural compound with chemo for advanced colorectal cancer
This trial combines a natural substance called hydroxytyrosol (HT) with standard chemotherapy (5-FU and possibly other drugs) for people with advanced or metastatic colorectal cancer that hasn't been treated yet. The goal is to see if adding HT makes the treatment work better.
Houston, TexasAges 18 years+ - NCT06824064RecruitingPhase 2
RBS2418 for advanced metastatic colorectal cancer
This trial tests a new drug called RBS2418 for people with advanced colorectal cancer that has spread and is getting worse, even after other treatments have stopped working. The goal is to see if RBS2418 can help control the cancer.
Newark, DelawareAges 18 years+ - NCT06811116RecruitingPhase 1/Phase 2
Sapanisertib plus cabozantinib for advanced liver cancer
This trial studies a combination of two drugs for advanced liver cancer with a specific gene change. The goal is to see if adding sapanisertib to the usual cabozantinib treatment helps people live longer without their cancer growing.
Irvine, CaliforniaAges 18 years+ - NCT06803680RecruitingPhase 1
Study of BGB-B455 for advanced solid tumors
This trial tests a new drug, BGB-B455, for people with advanced solid tumors that have not responded to other treatments. It focuses on tumors that have a specific marker called CLDN6, especially in ovarian cancer.
Celebration, FloridaAges 18 years+ - NCT06805617RecruitingPhase 2
Ivonescimab for advanced salivary gland cancer
This trial tests a new drug called Ivonescimab for people with advanced salivary gland cancer that has spread or cannot be removed surgically. The goal is to see if the drug can shrink tumors or slow cancer growth.
Boston, MassachusettsAges 18 years+ - NCT05755672Recruiting
Study biomarkers during curative-intent treatment for metastatic colon cancer
This study looks at biological markers (substances measured in the body) during treatment for metastatic colorectal cancer. It may help doctors better understand how treatment works, using patients who are treated with a goal of cure.
Lund, Skåne CountyAges 18–110
Hear when a new Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic?
- Yes. Clin2 currently lists 2,342 recruiting metastatic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.